VIDEO: Stelara safe, effective for the long-term treatment of moderate to severe UC

VIENNA — In a Healio video exclusive, Waqqas Afif, MD, reports results from the phase 3 UNIFI study, in which Stelara safely demonstrated sustained symptomatic and corticosteroid-free remission in adults with ulcerative colitis.According to Afif, 65% of patients who responded to the induction dose of Stelara (ustekinumab, Janssen) were in remission after 44 weeks of maintenance therapy. At 4 years, 55% of patients in the long-term extension period achieved symptomatic remission, with 96% no longer receiving corticosteroids. Researchers also noted no new safety signals.“In general,Read More